2011 Scrip 100: Reinventing invention
This article was originally published in Scrip
Executive Summary
All leading pharmaceutical companies balance close to the edge of the patent cliff, but the ways in which they respond to their precarious positions are different. Dr John Lechleiter, CEO of Lilly, tells Mike Ward that he believes the answer lies with improving the economics of innovation.